Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 study evaluating infectivity, safety, and immunogenicity of a recombinant live-attenuated RSV vaccine (LID/ΔM2-2/1030s) in RSV-seronegative infants and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• LID/ΔM2-2/1030s

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: RSV Infection | Phase 1 | Status: COMPLETED | Results posted: 2025-08-22